CONNECT WITH US
HealthTech

HealthTech

CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug

Endpoints News logo

Published on

Add as a preferred source on Google
CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug

CSL to pay $355M up­front to co-de­vel­op Alen­tis’ kid­ney and liv­er drug

The Aus­tralian drug­mak­er CSL will pay $355 mil­lion for Alen­tis Ther­a­peu­tics’ an­ti-fi­bro­sis drug, plus as much as $1.2 bil­lion in fu­ture pay­ments.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In­sur­er start­up De­vot­ed Health rais­es $1.2B as it revs up growth October 1, 2026

Ex­clu­sive: Af­ter No­vo obe­si­ty deal, Kally­ope re­brands and gets $94M for mi­graine tri­als October 1, 2026

Sanofi builds on im­munol­o­gy al­liance with Re­gen­eron for $1B up­front October 1, 2026

Lil­ly sig­nals move in­to aes­thet­ics, look­ing to add prod­ucts for body, skin and hair

No­var­tis takes rights to Abo­gen's mR­NA T cell en­gager for $575M up­front

Mod­er­na, Neu­ro­crine bring back fa­mil­iar faces; Pharm­ing CEO ex­its af­ter clash­ing with board



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.